Glaukos Corporation Stock News

Glaukos Corp:

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today pr

Man Group plc lowered its position in shares of Glaukos Corp (NYSE:GKOS) by 70.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institu

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

Cubist Systematic Strategies LLC decreased its position in Glaukos Corp (NYSE:GKOS) by 58.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm ow

Glaukos Corp (NYSE:GKOS) has earned an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat.com reports. Three research analysts have r

Bank of America Corp DE cut its holdings in Glaukos Corp (NYSE:GKOS) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor own

Glaukos (NYSE:GKOS) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendat

Glaukos (NYSE:GKOS) had its price objective decreased by Citigroup from $40.00 to $36.00 in a report released on Friday, BenzingaRatingsTable reports. Citigroup currently has a sell rating on the medi

Great West Life Assurance Co. Can acquired a new stake in shares of Glaukos Corp (NYSE:GKOS) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,412 shares of the medical instr

Amalgamated Bank lifted its position in Glaukos Corp (NYSE:GKOS) by 15.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,269 shares

Wall Street analysts expect Glaukos Corp (NYSE:GKOS) to post $61.06 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Glaukos’ earnings. The lowest sales